Overview
HCWB market data
Price History
HCWB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.02 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.25 – $8.75 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $13.1 · P/B 0.95 · P/S 1.99.
Company news
HCW Biologics shares are trading lower. The company announced it has requested Type B pre-IND meeting with the FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b.Benzinga · Jul 23, 2026, 5:13 PM
HCW Biologics Requests For Type B Meeting With FDA To Discuss Development, Regulatory Path For Its HCW11-018b Candidate To Treat Solid TumorsBenzinga · Jul 23, 2026, 12:02 PM
8-K filing — HCW Biologics Inc. (HCWB)SEC EDGAR · Jul 1, 2026, 12:30 PM
HCW Biologics Regains Nasdaq Compliance After Announcing 1-For-6 Reverse Stock Split, Effective June 30Benzinga · Jun 30, 2026, 12:30 PM
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026Globenewswire Inc · Jun 26, 2026, 1:15 PM
HCW Biologics Announces 1-For-6 Reverse Stock Split, Effective June 30Benzinga · Jun 26, 2026, 1:05 PM
Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair LossBenzinga · Jun 16, 2026, 2:25 PM
HCW Biologics Says Preliminary Human Data For The First Two Dose Cohorts From Its Dose-escalating Phase 1 Trial Of HCW9302 For Alopecia Areata Shows Clinical Response After Single Dose AdministrationBenzinga · Jun 16, 2026, 11:15 AM
HCW Biologics Files Prospectus For Offering 5.69M Common SharesBenzinga · Jun 8, 2026, 2:20 PM
Maxim Group Maintains Buy on HCW Biologics, Raises Price Target to $5Benzinga · May 28, 2026, 6:43 PM